Tag Archives: Taltz

Lilly tees up another Novartis battle with ankylosing spondylitis OK for Taltz

Eli Lilly’s Taltz is cruising toward blockbuster territory, and now it has a new indication to help it get there. Monday, the FDA green-lighted the drug in ankylosing spondylitis (AS), adding to the go-aheads it received in December 2017 for psoriatic arthritis (PsA) and in March 2016 for plaque psoriasis. With the new launch, Lilly… Read More »